Increased prevalence of anti-third generation cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis and CREST syndrome

Clinical Reviews in Allergy and Immunology

Volumn 32, Issue 1, 2007, Pages 47-55

  Wu, R ^a   Shovman, O ^b   Zhang, Y ^c   Gilburd, B ^b   Zandman Goddard, G ^b   Shoenfeld, Yehuda ^b,d  

^a Pathway Diagnostics Corp   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

^c Premiere Oncology   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Anti CCP; Antibodiies; CREST syndrome; Rheumatoid arthritis

Indexed keywords

CENTROMERE ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY;

ANKYLOSING SPONDYLITIS; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; CONFERENCE PAPER; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CROSS REACTION; DERMATOMYOSITIS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; OSTEOARTHRITIS; POLYMYOSITIS; PREVALENCE; REACTIVE ARTHRITIS; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SCLERODERMA; SENSITIVITY AND SPECIFICITY; SJOEGREN SYNDROME; SYNDROME CREST; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 34247116913     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02686081     Document Type: Conference Paper

References (39)

1. Von Muhien and Tan, E. M. (1995), Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum. 24, 323-358.
2. Senshu, T., Kan, S., Ogawa, H., Manabe, M., and Asaga, H (1996), Preferential deimination of keratin K1 and filaggrin during the terminal differentiation of human epidermis. Biochem Biophys Res Commun 225, 712-719.
3. Vossenaar, E. R., Zendman, A. J., van Venrooij, W. J., Pruijn, G. J., (2003), PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioassays 25, 1106-1118.
4. ACR Subcommittee on RA Guidelines (2002), Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 46, 328-346.
5. Goldbach-Mansky, R., Lee, J., McCoy, A., et al. (2000), Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2, 236-243.
6. Schellekens, G. A., de Jong, B. A., van den Hoogen, F. H., van de Putte, L. B., and van Venrooij, W. J. (1998), Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101, 273-281.
7. Schellekens, G. A., Visser, H., de Jong, B. A., et al. (2000), The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinate peptide. Arthritis Rheum 43, 155-163.
8. Nielen, M. M., van Schaardenburg, D., Reesink, H. W., et al. (2004), Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50, 380-386.
9. Rantapaa-Dahlqvist, S., de Jong, BA., Berglin, E., et al. (2003), Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48, 2741-2749.
10. Suzuki, K., Sawada, T., Murakami, A., et al. (2003), High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 32, 197-204.
11. Agrawal, S., Misra, R., and Aggarwal, A. (2007), Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol 26, 201-204.
12. Shovman, O., Gilburd, B., Zandman-Goddard, G., et al. (2005), The diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis. Clin Dev Immunol 12, 197-202.
13. Vencovsky, J., Machacek, S., Sedova, L., et al. (2003), Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 62, 427-430.
14. Meyer, O., Labarre, C., Dougados, M., et al. (2003), Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62, 120-126.
15. Forslind, K., Ahlmen, M., Eberhardt, K., et al. (2004), Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63, 1090-1095.
16. Visser, H., le Cessie, S., Vos, K., Breedveld, F. C., and Hazes, J. M. (2002), How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 46, 357-365.
17. Orbach, H., Gilburd, B., Brickman, C., Gerli, R., and Shoenfeld, Y. (2002), Anti-cyclic peptide antibodies as a diagnostic test for rheumatoid arthritis and predictor of an erosive disease. IMAJ 4, 892-893.
18. Baeten, D., Peene, I., Union, A., et al. (2001), Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum 44, 2255-2262.
19. van Boekel, M. A., Vossenaar, E. R., van den Hoogen, F. H., van Venrooij, W. J. (2002), Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 4, 87-93.
20. Vossenaar, E. R. and van Venrooij, W. J. (2004) Anti-CCP antibodies, a specific marker for (early) rheumatoid arthritis. Clin Appl Immunol Rev 4, 239-262.
21. Vallbracht, I., Rieber, J., Oppermann, M., Forger, F., Siebert, U., and Helmke, K. (2004), Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63, 1079-1084.
22. Bas, S., Genevay, S., Meyer, O., and Gabay, C. (2003), Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 42, 677-680.
23. van Jaarsveld, C-. H., ter Borg, E. J., Jacobs, J. W., et al. (1999), The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol. 17, 689-697.
24. Saraux, A., Berthelot, J. M., Devauchelle, V., et al. (2003), Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis. J Rheumatoln 30, 2535-2539.
25. Vittecoq, O., Incaurgarat, B., Jouen-Beades, F., et al. (2004), Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol 135, 173-180.
26. Arnett, F. C., Edworthy, S. M., Bloch, D. A., et al. (1988), The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31, 315-324.
27. Zeng, X., Ai, M., Tian, X., et al. (2003), Diagnostic value of anti-cyclic citrullinated Peptide antibody in patients with rheumatoid arthritis. J Rheumatol 30, 1451-1455.
28. Mediwake, R., Isenberg, D. A., Schellekens, G. A., and van Venrooij, W. J. (2001), Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 60, 67-68.
29. Lopez-Hoyos, M., Ruiz de Alegria, C., Blanco, R., et al. (2004), Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology (Oxford) 43, 655-657.
30. Gottenberg, J. E., Mignot, S., Nicaise-Rolland, P., et al. (2005), Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjogren's syndrome. Ann Rheum Dis 64, 114-147.
31. Kamali, S., Polat, N. G., Kasapoglu, E., et al. (2005), Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjogren's syndrome, and Wegener's granulomatosis. Clin Rheumatol 24, 673-676.
32. Alenius, G. M., Berglin, E., Rantapaa Dahlqvist, S. (2006), Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis 65, 398-400.
33. Vossenaar, E. R., Smeets, T. J., Kraan, M. C., Raats, J. M., van Venrooij, W. J., and Tak, P. P. (2004), The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 50, 3485-3494.
34. Fritzler, M. J. and Kinsella, T. D. (1980), The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 69, 520-526.
35. Weiner, E. S., Earnshaw, W. C., Senecal, J. L., Bordwell, B., Johnson, P., and Rothfield, N. F. (1988), Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum 31, 378-385.
36. Tan, E. M., Rodnan, G. P., Garcia, I., Moroi, Y., Fritzler, M. J., and Peebles, C. (1980), Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 23, 617-625.
37. Caramaschi, P., Biasi, D., Manzo, T., Carletto, A., Poli, F., and Bambara, L. M. (1995), Anticentromere antibody - clinical associations. A study of 44 patients. Rheumatol Int 14, 253-255.
38. Zuber, M., Gotzen, R., Filler, I. (1994), Clinical correlation of anticentromere antibodies. Clin Rheumatol 13, 427-432.
39. Miyawaki, S., Asanuma, H., Nishiyama, S., and Yoshinaga, Y. (2005), Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol 32, 1488-1494.